Nebulized pH-Responsive Nanospray Combined with Pentoxifylline and Edaravone to Lungs for Efficient Treatments of Acute Respiratory Distress Syndrome

• DOI: 10.1021/acsami.3c15691
• Publication Date: 2024-02-12T05:39:31Z
• Authors: Ruihao Li; Xiaochun Hu; Wenhui Li; Wenjing Wu; Jin Xu; Yun Lin; Shuo Shi; Chunyan Dong
• Keywords: Pentoxifylline; Proinflammatory cytokine; Edaravone; Free radical scavenger

The COVID-19 pandemic has become an unprecedented global medical emergency, resulting in more than 5 million deaths. Acute respiratory distress syndrome (ARDS) caused by COVID-19, characterized the release of a large number pro-inflammatory cytokines and production excessive toxic ROS, is most common serious complication leading to death. To develop new strategies for treating ARDS mouse model was established using lipopolysaccharide (LPS). Subsequently, we have constructed novel nanospray with anti-inflammatory antioxidant capacity loading pentoxifylline (PTX) edaravone (Eda) on zeolite imidazolate frameworks-8 (ZIF-8). This endowed synergetic therapy, which could kill two birds one stone: (1) loaded PTX played powerful role inhibiting activation inflammatory cells synthesis cytokines; (2) Eda served as free radical scavenger ARDS. Furthermore, compared traditional intravenous administration, nanosprays can be administered directly inhaled efficiently reduce risk systemic adverse reactions greatly. not only coload drugs but also realize acid-responsive local lung tissue. Importantly, ZIF8-EP showed excellent therapeutic effect vitro vivo, provided direction treatment